Education
About Us
Working with TipRanks
Follow Us
Mineralys Therapeutics, Inc. (MLYS)
NASDAQ:MLYS
Total Valuation
Mineralys Therapeutics, Inc. has a market cap or net worth of $2.91B. The enterprise value is $2.08B.
Market Cap$2.91B
Enterprise Value$2.08B
Share Statistics
Mineralys Therapeutics, Inc. has 79,139,950 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding79,139,950
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Mineralys Therapeutics, Inc.’s return on equity (ROE) is -0.93 and return on invested capital (ROIC) is -100.60%.
Return on Equity (ROE)-0.93
Return on Assets (ROA)-0.86
Return on Invested Capital (ROIC)-100.60%
Return on Capital Employed (ROCE)-1.01
Revenue Per Employee0.00
Profits Per Employee-3.49M
Employee Count51
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Mineralys Therapeutics, Inc. is ―. Mineralys Therapeutics, Inc.’s PEG ratio is -0.04.
PE Ratio―
PS Ratio0.00
PB Ratio3.12
Price to Fair Value3.12
Price to FCF-3.59
Price to Operating Cash Flow-13.10
PEG Ratio-0.04
Income Statement
In the last 12 months, Mineralys Therapeutics, Inc. had revenue of 0.00 and earned -177.81M in profits. Earnings per share was -3.66.
Revenue0.00
Gross Profit-43.00K
Operating Income-192.40M
Pretax Income-177.81M
Net Income-177.81M
EBITDA-192.36M
Earnings Per Share (EPS)-3.66
Cash Flow
In the last 12 months, operating cash flow was -171.37M and capital expenditures 0.00, giving a free cash flow of -171.37M billion.
Operating Cash Flow-171.37M
Free Cash Flow-171.37M
Free Cash Flow per Share-2.17
Dividends & Yields
Mineralys Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.21
52-Week Price Change198.46%
50-Day Moving Average40.80
200-Day Moving Average24.10
Relative Strength Index (RSI)41.34
Average Volume (3m)1.72M
Important Dates
Mineralys Therapeutics, Inc. upcoming earnings date is Mar 18, 2026, After Close (Confirmed).
Last Earnings DateNov 10, 2025
Next Earnings DateMar 18, 2026
Ex-Dividend Date―
Financial Position
Mineralys Therapeutics, Inc. as a current ratio of 14.02, with Debt / Equity ratio of 0.00%
Current Ratio14.02
Quick Ratio14.02
Debt to Market Cap0.00
Net Debt to EBITDA0.59
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Mineralys Therapeutics, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Mineralys Therapeutics, Inc. EV to EBITDA ratio is -2.51, with an EV/FCF ratio of -2.91.
EV to Sales0.00
EV to EBITDA-2.51
EV to Free Cash Flow-2.91
EV to Operating Cash Flow-2.91
Balance Sheet
Mineralys Therapeutics, Inc. has $217.60M in cash and marketable securities with $0.00 in debt, giving a net cash position of $217.60M billion.
Cash & Marketable Securities$217.60M
Total Debt$0.00
Net Cash$217.60M
Net Cash Per Share$2.75
Tangible Book Value Per Share$3.94
Margins
Gross margin is -26.47%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-26.47%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Mineralys Therapeutics, Inc. is $52.60, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$52.60
Price Target Upside42.16% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast9.60%